Edwards Lifesciences beats on revenue but forecast lags estimates

(Reuters) - U.S. medical device maker Edwards Lifesciences narrowly topped Wall Street estimates for quarterly revenue on Thursday as it sold more heart monitors, but its outlook for March quarter earnings fell below analysts' forecasts. The company's critical care business, which houses its HemoSphere heart monitoring systems, had sales of $178 million in the final quarter of 2018, up 8 percent from a year earlier. The U.S. ...